Drug Approval | June 11, 2026
AstraZeneca gets CDSCO nod for Trastuzumab Deruxtecan plus Pertuzumab
Approval expands treatment options for patients with unresectable or metastatic HER2-positive breast cancer
Approval expands treatment options for patients with unresectable or metastatic HER2-positive breast cancer
The validation confirms the submission is complete, clearing the way for the EMA’s centralized review process to formally evaluate the therapy
The award places the company in the top 5% globally
Accomplished molecular microbiologist and protein engineer takes charge of CSIR-IMTECH after serving in key scientific and regulatory leadership roles at FSSAI
7.5 crore antenatal check-ups and 1.2 crore high-risk pregnancies identified under flagship programme as maternal and neonatal mortality declines
The company gets access to Lonza’s clinically validated SYNtecan linker-payload platform as it prepares an IND filing for its acute myeloid leukemia therapy in 2027
The acquisition reflects Johnson & Johnson’s push to strengthen its position in antibody engineering and next-generation oncology modalities
The landmark legislation has laid the foundation for a skilled, regulated and globally competitive Allied and Healthcare Professional workforce, reshaping healthcare education and delivery across India
Bengaluru-based startup will use the fresh capital to enter new markets, enhance technology capabilities, and scale its integrated care model
Consolidated entity plans to strengthen specialty pharmaceutical offerings, expand manufacturing capacity, and accelerate global market penetration across emerging regions
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
